Dabomb Protein (6578) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dabomb Protein (6578) has a cash flow conversion efficiency ratio of 0.000x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-354.00K ≈ $-11.15K USD) by net assets (NT$989.28 Million ≈ $31.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Dabomb Protein liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Dabomb Protein - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Dabomb Protein's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dabomb Protein Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dabomb Protein ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harn Engineering Solutions Public Company Limited
BK:HARN
|
0.006x |
|
Apex Equity Holdings Bhd
KLSE:5088
|
-0.044x |
|
Estrella Resources Ltd
AU:ESR
|
-0.064x |
|
P&K Skin Research Center Co. Ltd
KQ:347740
|
0.021x |
|
Team Young Advanced Technology Co Ltd
TWO:5345
|
-0.242x |
|
Apollo Sindoori Hotels Limited
NSE:APOLSINHOT
|
0.001x |
|
Compumedics Ltd
AU:CMP
|
0.129x |
|
The Beachbody Company, Inc.
NASDAQ:BODI
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Dabomb Protein (2015–2025)
The table below shows the annual cash flow conversion efficiency of Dabomb Protein from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Dabomb Protein market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$989.28 Million ≈ $31.17 Million |
NT$16.65 Million ≈ $524.44K |
0.017x | -61.46% |
| 2024-12-31 | NT$1.09 Billion ≈ $34.32 Million |
NT$47.55 Million ≈ $1.50 Million |
0.044x | +542.86% |
| 2023-12-31 | NT$958.06 Million ≈ $30.18 Million |
NT$6.51 Million ≈ $204.97K |
0.007x | -74.94% |
| 2022-12-31 | NT$727.20 Million ≈ $22.91 Million |
NT$19.71 Million ≈ $620.85K |
0.027x | +141.29% |
| 2021-12-31 | NT$674.24 Million ≈ $21.24 Million |
NT$-44.25 Million ≈ $-1.39 Million |
-0.066x | -442.83% |
| 2020-12-31 | NT$700.51 Million ≈ $22.07 Million |
NT$13.41 Million ≈ $422.52K |
0.019x | -59.80% |
| 2019-12-31 | NT$698.39 Million ≈ $22.00 Million |
NT$33.26 Million ≈ $1.05 Million |
0.048x | +53.30% |
| 2018-12-31 | NT$710.52 Million ≈ $22.39 Million |
NT$22.07 Million ≈ $695.42K |
0.031x | -55.90% |
| 2017-12-31 | NT$622.77 Million ≈ $19.62 Million |
NT$43.87 Million ≈ $1.38 Million |
0.070x | -26.73% |
| 2016-12-31 | NT$619.77 Million ≈ $19.53 Million |
NT$59.58 Million ≈ $1.88 Million |
0.096x | -59.24% |
| 2015-12-31 | NT$592.64 Million ≈ $18.67 Million |
NT$139.78 Million ≈ $4.40 Million |
0.236x | -- |
About Dabomb Protein
DaBomb Protein Biotech Corp. manufactures and sells hydrolyzed soy protein in Vietnam, the Philippines, South Korea, Taiwan, and Asia. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its n… Read more